[wpml_language_selector_widget]

Medical Uses

At this time only one FDA-approved cannabidiol is available for patients with select drug-resistant seizure disorders.1 In 2018 the FDA approved the first prescription cannabidiol product, which is indicated for severe seizures associated with three rare forms of developmental and epileptic encephalopathy in patients 1 year of age and older. The three types are:

  • Dravet syndrome
  • Lennox-Gastaut syndrome
  • Tuberous sclerosis complex

This CBD agent is derived from cannabis plants that have been grown in a controlled environment. There are no genetic modifications so the product meets FDA and World Health Organization (WHO) agricultural and manufacturing standards.2 It is highly purified so that the active ingredient is nearly 100% CBD. It is also rigorously tested to ensure quality and consistency with labeling for each product.2 This product was approved by the FDA following the determination that the product met quality standards and demonstrated safety and efficacy for epilepsy use in controlled clinical trials.

Cannabidiol Administration

References

  1. Cannabidiol (Epidiolex®) oral solution. Prescribing information, 2024. Accessed 8/3/2024. https://pp.jazzpharma.com/pi/epidiolex.en.USPI.pdf
  2. Greenwich Biosciences. Cannabinoids 101: Understanding CBD, 2020. Accessed 8/3/2024. https://www.epidiolexhcp.com/sites/default/files/cbd-facts.pdf

Pin It on Pinterest

Scroll to Top

You are now leaving the THRIVE site

The THRIVE Neuroscience Community of Care site is funded by an independent medical education grant from Jazz Pharmaceuticals. The following site is not affiliated with the THRIVE educational initiative and MLG is not responsible for its content.

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers